Cure8 research brief
Noninvasive fecal calprotectin levels tracked with endoscopic disease activity in children with colonic Crohn's disease, suggesting FC could help reduce repeat endoscopies and better monitor treatment response.
Pediatric patients with Crohn's disease (and their parents/caregivers), pediatric gastroenterologists, and researchers interested in biomarkers for IBD monitoring.
This retrospective, multicenter cross-sectional analysis included 154 pediatric patients with Crohn's disease confined to the colon. At diagnosis median FC was high (1,355 mg/kg) and fell at follow-up (median 126 mg/kg) alongside lower SES-CD scores; about half achieved endoscopic remission at follow-up.
The authors report that FC correlated more strongly with endoscopic findings than with clinical scores or serum markers and suggest clinically useful FC cutoff values to reduce the need for repeat endoscopy.
Practical takeaways For caregivers and clinicians, the study supports using fecal calprotectin as a surrogate marker to monitor mucosal inflammation in pediatric colonic CD and to help guide decisions about the timing of endoscopy. The proposed cutoffs could be useful in real-world practice but should be interpreted in the context of each clinical setting.
This record is an abstract-level, retrospective multicenter study. Cutoff values and correlations reported here are based on the study cohort (pediatric patients with colonic CD in Korea) and should be validated in other populations and prospective studies before changing practice universally.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
